Hormonal Agents Lead to Improved Outcomes in African Americans With Chemo-Naive mCRPC

Megan McNamara, MD

Although African-American men are at a higher risk for metastatic castration-resistant prostate cancer (mCRPC) and have worse survival outcomes compared with Caucasian men, findings of a recent retrospective study suggested they may have a better response to several prostate cancer treatments.

The large study, presented during a presscast ahead of the 2019 Genitourinary Cancers Symposium, showed African-American mCRPC treated with novel hormonal therapies—namely abiraterone acetate (Zytiga) or enzalutamide (Xtandi)—lived 20% longer than their Caucasian counterparts.

Moreover, the median overall survival (OS) was 30 months in African-American patients, compared with 26 months in Caucasian patients—highlighting the need for prospective trials to validate these findings, said Megan McNamara, MD, an assistant professor of medicine at Duke University School of Medicine, during the presscast.

The unadjusted analysis demonstrated superior outcomes among African-American patients, with a median Kaplan-Meier estimated OS of 910 days compared with 784 days in Caucasian patients (HR, 0.887; 95% CI, 0.790-0.996;P= .0435).

Similarly, after adjusting for demographic and clinical characteristics available in the Veterans’ Health Administration (VHA) database, these findings were confirmed as African-American men still showed superior survival outcomes, with a median Kaplan-Meier estimated OS of 918 days compared with 781 days among white men (HR, 0.826; 95% CI, 0.732-0.933;P= .0020).

“When controlling for access to care through a single payer system—in this case the VHA health system—in chemotherapy-naïve metastatic castration-resistant prostate cancer patients, African Americans may have better overall survival than Caucasians treated when with abiraterone acetate or enzalutamide,” McNamara said.

“For example, an analysis of pooled data from men with metastatic castrate-resistant prostate cancer who were treated with docetaxel in 9 different randomized phase III trials actually showed better survival among African-American men when treated with docetaxel, compared with Caucasians,” McNamara explained. “Similarly, African-American patients have been shown to have longer survival compared to Caucasians when treated with the immunotherapy sipuleucel-T (Provenge). And, a third study suggested African-American men with metastatic castrate-resistant prostate cancer had better [prostate-specific antigen (PSA)] response to abiraterone, compared to Caucasian patients.”

With a paucity of data to confirm these findings, the researchers analyzed 5 years’ worth of data from the VHA from April 2013 to March 2018 to determine OS outcomes in African-American men with chemotherapy-naïve mCRPC who were treated with abiraterone acetate or enzalutamide. Data included men with prostate cancer who were 18 years or older, whose only prior treatment was surgical or medical castration. Among men with disease that had progressed, researchers included only those who had been treated with either abiraterone acetate or enzalutamide. Patients were monitored for health outcomes until they disenrolled from the study or the VHA or died. Overall survival was defined as the interval from the first prescription claim for abiraterone acetate or enzalutamide following castration—for example, the Index date—to the date of death.

The analysis included data from 2123 Caucasian men (mean age, 74) followed for a median of 570 days and 787 African-American men (mean age, 71) followed for a median 561 days. African-American men reported with higher rates of hypertension (77.1% vs 67.1%;P<.0001), type II diabetes (38.1% vs 29.3%;P<.0001), and liver damage or abnormality (8.8% vs 5.2%;P= .0003), compared with Caucasian men in the study.

&ldquo;These retrospective data emphasize the need for prospective trials to validate these findings and investigate the mechanism underlying racial disparities in survival outcomes between African Americans and Caucasians with metastatic castration resistant prostate cancer when treated with these novel hormonal therapies,&rdquo; McNamara concluded.

ASCO expert and presscast moderator Robert Dreicer, MD, MS, MACP, FASCO, agreed with the importance of these findings, highlighting the need to better understand the difference in racial disparities among men with castration-resistant prostate cancer.

&ldquo;These data are very provocative and it adds to an emerging database that has confirmed prospectively and has changed the way we think about racial differences,&rdquo; he added.

Reference:

McNamara M, George DJ, Ramaswamy K, et al. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.J Clin Oncol.2019;37 (suppl; abstr 212).